BioCentury
ARTICLE | Clinical News

EryDel's EryDex meets Phase II endpoint

March 1, 2012 1:11 AM UTC

EryDel S.p.A. (Urbino, Italy) said EryDex encapsulated in autologous erythrocytes met the primary endpoint in a Phase II trial in 22 patients with genetically-confirmed ataxia telangiectasia. The prod...